Shi J, Yong-yong H, Ju-Xian S, Wei-Xing G, Li N, Xue J, Shu-Qun C

Idioma: Ingles.
Referencias bibliográficas: 20
Paginas: 198-206
Archivo PDF: 230.27 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Esnaola NF, Mirza N, LauwersGY, Ikai I, Regimbeau JM, Belghiti J, Yamaoka Y, et al. Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg 2003; 238: 711-9.

2. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, Miller CM, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235: 533-9.

3. Poon RT, Fan ST, Ng IO, Wong J. Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg 2003; 237: 376-83.

4. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso M del C, Sala M, Brú C, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-7.

5. Takabe K, Paugh SW, Milstien S, Spiegel S. Inside-out signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008; 60: 181-95.

6. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010;10: 489-503.

7. Nagahashi M, Ramachandran S, Kim EY, Allegood JC, Rashid OM, Yamada A, Zhao R, et al. Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Res 2012; 72: 726-35.

8. Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW, D’Andrea RJ, et al. An oncogenic role of sphingosine kinase. Curr Biol 2000; 10: 1527-30.

9. Milstien S, Spiegel S. Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics. Cancer Cell 2006; 9: 148-50.

10. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grösch S, et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008; 112: 41-52.

11. Li W, Yu CP, Xia JT, Zhang L, Weng GX, Zheng HQ, Zheng HQ, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2009; 15: 1393-9.

12. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 2005; 64: 695-705.

13. Shi J, Lai EC, Li N, GuoWX, Xue J, Lau WY, Wu MC, et al. A new classification for hepatocellular carcinoma with portal vein tumor thrombus. J Hepatobiliary Pancreat Sci 2011; 18: 74-80.

14. Shi J, Lai EC, Li N, Guo WX, Xue J, Lau WY, Wu MC, et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol 2010; 17: 2073-80.

15. Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, Chung AY, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg 2011; 254: 108-13.

16. Wang T, Hu HS, FengYX, Shi J, Li N, GuoWX, Xue J, et al. Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma. Br J Cancer 2010; 102: 1618-26.

17. Hu L, Lau SH, Tzang CH, Wen JM, Wang W, Xie D, Huang M, et al. Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 2004; 23: 298- 302.

18. Bao M, Chen Z, Xu Y, Zhao Y, Zha R, Huang S, Liu L, et al. Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma. Liver Int 2012; 32: 331-8.

19. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.

20. Wang JH, Kuo YH, Wang CC, Chen CL, Cheng YF, Hsu HC, Lu SN. Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. Dig Liver Dis 2013; 45: 510-5.